<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00285389</url>
  </required_header>
  <id_info>
    <org_study_id>MANTEAU 2001</org_study_id>
    <nct_id>NCT00285389</nct_id>
  </id_info>
  <brief_title>Treatment of Mantle Cell Lymphoma at Diagnosis for Patients Under 65 Years</brief_title>
  <official_title>Treatment in First Line of Mantle Cell Lymphoma for Patients Under 66 Years by the VAD-CHLORAMBUCIL -Rituximab Regimen Followed by Intensification and Autologous PBSC Transplantation After Marrow Purging With Rituximab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>French Innovative Leukemia Organisation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>French Innovative Leukemia Organisation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase II study to test in first line the VAD (Vincristine Adriablastine Dexamethasone) + C
      (Chlorambucil ) regimen associated to rituximab ( R-VAD + C ) in a cohort of young patients
      under 66 years with a mantle cell lymphoma and also the test the role of an in vivo marrow
      purge with rituximab before an autologous stem cell transplantation for the consolidation of
      the patients which fulfilled a response to 4 cycles of (R VAD + C) regimen.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All patients at diagnosis with a stage II, III or IV an arbor disease are treated with 4
      cycles of (R VAD +C) .

      The responders more than RP &gt; 50% received 2 other cycles before to be intensified with
      alkeran 140 mg/ m2 and a 8 grays TBI over 4 days before an autologous PBSCT.The stem cell
      collection is realised after a mobilisation with HD Cyclophosphamide (4 mg/m2) after the four
      R-(VAD + C) cycles and purged by a rituximab injection 10 days before the collection.

      There is an clinical and molecular evaluation of the strategy
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2002</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>failure event free survival at 3 years</measure>
    <time_frame>3 YEARS</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate after 4 R-(VAD+C) cycles</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incident of Molecular residual disease on blood, marrow and stem cell collection</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of the R-( VAD+C) regimen</measure>
    <time_frame>8 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of the stem cell collection after HD Cyclosphosphamide mobilization and rituximab purging</measure>
    <time_frame>8 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Mantle Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>VAD Clorambucil Rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adriblastin</intervention_name>
    <arm_group_label>VAD Clorambucil Rituximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
    <arm_group_label>VAD Clorambucil Rituximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chlorambucil</intervention_name>
    <arm_group_label>VAD Clorambucil Rituximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rituximab</intervention_name>
    <arm_group_label>VAD Clorambucil Rituximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <arm_group_label>VAD Clorambucil Rituximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>alkeran</intervention_name>
    <arm_group_label>VAD Clorambucil Rituximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Total body irradiation (8Gy/4fr)</intervention_name>
    <arm_group_label>VAD Clorambucil Rituximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine</intervention_name>
    <description>0,4 mg/day day 1 to day 4</description>
    <arm_group_label>VAD Clorambucil Rituximab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Mantel cell lymphoma

          -  CD 20+

          -  At diagnosis or without anterior chemotherapy

          -  Age &gt;18 and &lt; 66 years

          -  Ann Arbor ii, III or IV

          -  ECOG &lt;3

          -  contraindication for rituximab treatment

          -  Informed consent signed

          -  No cancer anteriory

          -  Renal and hepatic function compatible with the treatment

          -  Ventricular Fraction &gt; 50 % with echographic method and &gt; 40% with isotopic method

        Exclusion Criteria:

          -  Other type of lymphoma

          -  age&lt;18 ou &gt; 66 years

          -  Informed consent not signed

          -  anterior cancer

          -  Contraindication to rituximab

          -  Cardiac insufficiency
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Remy GRESSIN, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>French Innovative Leukemia Organisation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Regional university hospital</name>
      <address>
        <city>Besancon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional university hospital</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>REgional Hospital</name>
      <address>
        <city>Tours</city>
        <zip>37000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 31, 2006</study_first_submitted>
  <study_first_submitted_qc>January 31, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2006</study_first_posted>
  <last_update_submitted>February 11, 2009</last_update_submitted>
  <last_update_submitted_qc>February 11, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 12, 2009</last_update_posted>
  <responsible_party>
    <name_title>Dr Remy GRESSIN Principal Investigator</name_title>
    <organization>GOELAMS</organization>
  </responsible_party>
  <keyword>Mantle cell lymphoma</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Autologous PBSCT</keyword>
  <keyword>Molecular evaluation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Chlorambucil</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

